Clinical trial • Phase I • Dermatology
Clinical trial in Cutaneous T-cell lymphoma
Phase I trial for Cutaneous T-cell lymphoma. 35 participants.
Overview
- Trial Therapeutic Area
- Dermatology
- Trial Disease
- Cutaneous T-cell lymphoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 10-06-2025
- First CTIS Authorization Date
- 26-09-2025
Trial design
Phase I trial across 4 sites in France, Spain.
- Target Sample Size
- 35
Eligibility
Recruits 35 Vulnerable population not selected; no vulnerable population considerations or consent/assent handling mentioned..
- Vulnerable Population
- Vulnerable population not selected; no vulnerable population considerations or consent/assent handling mentioned.
Recruitment
- Planned Sample Size
- 35
- Recruitment Window Months
- 33
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 35
France
- Earliest CTIS Part Ii Submission Date
- 21-08-2025
- Latest Decision Or Authorization Date
- 26-09-2025
- Processing Time Days
- 36
- Number Of Sites
- 3
- Number Of Participants
- 32
Sites
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Dermatologie
- Contact Person Name
- Caroline RAM WOLFF
- Contact Person Email
- caroline.ram-wolff@aphp.fr
- Site Name
- Centre Hospitalier Universitaire De Bordeaux
- Department Name
- Dermatologie
- Contact Person Name
- Marie BEYLOT-BARRY
- Contact Person Email
- marie.beylot-barry@chu-bordeaux.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- Dermatologie
- Contact Person Name
- Stéphane DALLE
- Contact Person Email
- stephane.dalle@chu-lyon.fr
Spain
- Earliest CTIS Part Ii Submission Date
- 18-07-2025
- Latest Decision Or Authorization Date
- 01-10-2025
- Processing Time Days
- 75
- Number Of Sites
- 1
- Number Of Participants
- 3
Sites
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Dermatology
- Contact Person Name
- Pablo Luis ORTIZ ROMERO
- Contact Person Email
- pablo.ortiz@salud.madrid.org
Sponsor
Primary sponsor
- Full Name
- Assistance Publique Hopitaux De Paris
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Related trials
Other published trials that may interest you.
- N-[[(2S)-4-[(4-METHYL-1H-IMIDAZOL-5-YL)METHYL]-3-OXO-2-(PHENYLMETHYL)-1-PIPERAZINYL]CARBONYL]-L-LEUCINE TRIHYDRATE for Cutaneous T-cell lymphoma
- Tildrakizumab for Chronic spontaneous urticaria
- BARZOLVOLIMAB for Chronic spontaneous urticaria
- BIMEKIZUMAB for Plaque psoriasis | Psoriasis
- daratumumab for Toxic epidermal necrolysis